News

Video

Factors in Frontline Treatment Decision Making for Endometrial Cancer

Author(s):

Ritu Salani, MD,Bhavana Pothuri, MD

Key factors influencing frontline treatment choices in endometrial cancer, including biomarker status, comorbidities, guidelines, and patient preferences, with a focus on the evolving landscape of therapies.

Newsletter

Stay up to date on the most recent and practice-changing oncology data

Subscribe Now!
Related Videos
2 experts in this video
2 experts in this video
2 experts in this video
2 experts in this video
Matthew Wagar, MD of the University of Wisconsin School of Medicine and Public Health
2 experts in this video
Dr Salani on Novel Trial Designs and Therapies in Gynecologic Malignancies
Related Content
2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib
March 14th 2025

2024 Tumor-Agnostic Approval Cheat Sheet: T-DXd and Repotrectinib

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Global Oncology | Image Credit: © Katsyarina – stock.adobe.com
March 13th 2025

BLA Accepted in China for Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

Diane M. Simeone, MD; Marwan G. Fakih, MD
December 18th 2023

Simeone and Fakih Detail Research Objectives With A2B530 in CEA-Expressing Solid Tumors

Image Credit: Katsyarina – stock.adobe.com
March 6th 2025

Versamune HPV–Based Immunotherapy Combo Demonstrates Benefit in Advanced HPV-Associated Cancers

Matthew Wagar, MD
March 6th 2025

Immunotherapy Continues to Redefine Treamtent Considerations in Advanced/Recurrent Endometrial Cancer